Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sonnet Biotherapeutics Holdings Inc SONN

Consumer Cyclical Biotechnology
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.


NDAQ:SONN - Post by User

Sonnet Biotherapeutics Holdings Inc > SONN ....anyone going to swing this?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(72)
•••
Comment by Iseneschalon Aug 21, 2021 1:46pm
101 Views
Post# 33745162

RE:RE:RE:RE:SONN ....anyone going to swing this?

RE:RE:RE:RE:SONN ....anyone going to swing this?
MoMoneyNow wrote: No way! I ave'd down like a mofo as close to the bottom as possible. Bought in at .63 and .621. Missed that final bottom of .6008 by probably 30 secs haha! My average is .7155. I am prepared to lower it again as I expect that last ANNOYING dip before the offering close. Heading into eom now and I don't expect to recover loss for a few weeks. Fakken tfsa bank fees don't help. I'd like to believe this won't dip to low .50's but since I am in this it is going to happen. I am in a "decent" position here if you can call it that! I have learned that no matter WTF I do the first thing that happens when I buy a stock is I get FUKKED! So I immediately know not to go all in. I mean ffs how many times is an offering or p&d gonna curse me!? 


 Good to hear

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities